Table 9 Hazard ratios for comparing CCLG and GPOH patients

All patients

 Unadjusted

1.42 (1.13–1.77)

0.002

1.45 (1.14–1.86)

0.003

 Unadjusted HR, in localised disease only

1.47 (1.11–1.96)

0.007

1.52 (1.11–2.07)

0.009

 Adjusted for risk group and trial treatment

1.43 (1.14–1.79)

0.002

1.49 (1.17–1.91)

0.001

Adjusted for each of the following factors separately^a

 Age

1.45 (1.15–1.81)

0.001

1.47 (1.15–1.88)

0.002

 Metastatic disease

1.38 (1.10–1.73)

0.005

1.42 (1.11–1.81)

0.005

 Primary site

1.48 (1.18–1.86)

<0.001

1.52 (1.19–1.95)

0.001

 Histology

1.41 (1.12–1.77)

0.004

1.44 (1.12–1.85)

0.004

 Local treatment modality^b

1.45 (1.12–1.89)

0.006

1.30 (0.98–1.72)

0.07

 Adjusted for age, metastatic disease, primary site, histology and local treatment^a

1.44 (1.10–1.89)

0.009

1.30 (0.97–1.74)

0.08

 Adjusted HR, in localised disease only

1.48 (1.05–2.09)

0.026

1.29 (0.88–1.89)

0.19

Only patients who had local therapy; excluding progressive disease (n = 25) and where it was not known whether local therapy was given or not n = 22)

 Unadjusted

1.22 (0.96–1.55)

0.11

1.28 (0.99–1.67)

0.06

 Adjusted for type of local treatment^c

1.14 (0.87–1.51)

0.34

1.25 (0.92–1.68)

0.15

 Adjusted for time between the start of chemotherapy and starting local treatment

1.12 (0.87–1.44)

0.37

1.18 (0.90–1.55)

0.22

 Adjusted for age, metastatic disease, primary site, histology, local treatment, and time between the start of chemotherapy and starting local treatment

1.13 (0.84–1.50)

0.42

1.25 (0.91–1.71)

0.17